Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study | Zendy

Henry R. Kranzler | Zendy; Yukiko Washio | Zendy; Leah R. Zindel | Zendy; Kevin G. Lynch | Zendy; Dennis J. Hand | Zendy; Rachel F. Tyndale | Zendy; Cheryl Oncken | Zendy; Robert A. Schnoll | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study

Author(s) -

Henry R. Kranzler,

Yukiko Washio,

Leah R. Zindel,

Kevin G. Lynch,

Dennis J. Hand,

Rachel F. Tyndale,

Cheryl Oncken,

Robert A. Schnoll

Publication year - 2020

Publication title -

nicotine and tobacco research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.338

H-Index - 113

eISSN - 1469-994X

pISSN - 1462-2203

DOI - 10.1093/ntr/ntaa066

Subject(s) - cotinine , medicine , methadone , metabolite , opioid , nicotine , buprenorphine , placebo , anesthesia , receptor , alternative medicine , pathology

Pregnant women exposed chronically to opioids smoked more cigarettes per day (CPD) and had a higher nicotine metabolite ratio (NMR), 3-hydroxycotinine/cotinine, a biomarker of nicotine metabolism and clearance, than those not receiving opioids. We examined CPD and NMR in a group of pregnant smokers, a quarter of whom were receiving opioid agonist therapy (OAT).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research